Daniel Y C Heng

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2477127/publications.pdf

Version: 2024-02-01

135 papers	11,721 citations	53660 45 h-index	29081 104 g-index
137 all docs	137 docs citations	137 times ranked	9824 citing authors

#	Article	IF	Citations
1	Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factorâ€"Targeted Agents: Results From a Large, Multicenter Study. Journal of Clinical Oncology, 2009, 27, 5794-5799.	0.8	1,751
2	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2015, 373, 1814-1823.	13.9	1,004
3	External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncology, The, 2013, 14, 141-148.	5.1	808
4	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 917-927.	5.1	789
5	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncology, The, 2019, 20, 1370-1385.	5.1	594
6	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology, 2017, 35, 3851-3858.	0.8	384
7	Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2014, 66, 704-710.	0.9	382
8	The Impact of Cytoreductive Nephrectomy on Survival of Patients With Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. Journal of Urology, 2011, 185, 60-66.	0.2	322
9	The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncology, The, 2015, 16, 293-300.	5.1	299
10	Impact of Bone and Liver Metastases on Patients with Renal Cell Carcinoma Treated with Targeted Therapy. European Urology, 2014, 65, 577-584.	0.9	207
11	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 2445-2452.	3.2	193
12	Metastatic nonâ€"clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer, 2013, 119, 2999-3006.	2.0	189
13	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. Journal of Clinical Oncology, 2016, 34, 3655-3663.	0.8	174
14	Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group. Clinical Cancer Research, 2011, 17, 5443-5450.	3.2	164
15	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
16	A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet, The, 2021, 397, 695-703.	6.3	146
17	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. Journal of Clinical Oncology, 2017, 35, 2993-3001.	0.8	145
18	Change in Neutrophil-to-lymphocyte Ratio in Response to Targeted Therapy for Metastatic Renal Cell Carcinoma as a Prognosticator and Biomarker of Efficacy. European Urology, 2016, 70, 358-364.	0.9	133

#	Article	IF	Citations
19	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. Lancet Oncology, The, 2019, 20, 581-590.	5.1	124
20	Sunitinib rechallenge in metastatic renal cell carcinoma patients. Cancer, 2010, 116, 5400-5406.	2.0	123
21	Vascular endothelial growth factorâ€targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer, 2010, 116, 5219-5225.	2.0	121
22	Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy. Annals of Oncology, 2012, 23, 1549-1555.	0.6	121
23	Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncology, The, 2012, 13, 927-935.	5.1	112
24	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. Journal of Clinical Oncology, 2021, 39, 1563-1574.	0.8	108
25	Efficacy of Savolitinib vs Sunitinib in Patients WithMET-Driven Papillary Renal Cell Carcinoma. JAMA Oncology, 2020, 6, 1247.	3.4	105
26	Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. JAMA Network Open, 2021, 4, e2021869.	2.8	104
27	Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed) Tj ETQq1 1 0.784314 rgBT Factorâ€“Targeted Therapy in Patients With Advanced Renal Cell Carcinoma. European Urology, 2011, 59, 856-862.	0.9	99
28	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. Journal of Clinical Oncology, 2021, 39, 1553-1562.	0.8	83
29	Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma. European Journal of Cancer, 2015, 51, 2580-2586.	1.3	79
30	Progressionâ€free survival as a predictor of overall survival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer, 2011, 117, 2637-2642.	2.0	74
31	Everolimus plus exemestane as first-line therapy in HR+, HER2â^' advanced breast cancer in BOLERO-2. Breast Cancer Research and Treatment, 2014, 143, 459-467.	1.1	74
32	Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. European Urology, 2014, 65, 1086-1092.	0.9	71
33	First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. European Urology, 2019, 76, 861-867.	0.9	71
34	The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. European Urology, 2014, 65, 723-730.	0.9	69
35	Prognostic Significance of Bone Metastases and Bisphosphonate Therapy in Patients with Renal Cell Carcinoma. European Urology, 2014, 66, 502-509.	0.9	68
36	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	0.9	65

#	Article	IF	Citations
37	Prognostic Factors of Survival for Patients With Metastatic Renal Cell Carcinoma With Brain Metastases Treated With Targeted Therapy: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clinical Genitourinary Cancer, 2013, 11, 311-315.	0.9	64
38	Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy. Cancer Treatment Reviews, 2016, 50, 109-117.	3.4	64
39	A populationâ€based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer, 2009, 115, 776-783.	2.0	63
40	First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Journal of Cancer, 2016, 65, 102-108.	1.3	60
41	The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers, 2019, 11, 1713.	1.7	56
42	Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. , 2020, 8, e000144.		56
43	Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. Oncologist, 2017, 22, 286-292.	1.9	54
44	Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2018, 124, 3677-3683.	2.0	53
45	First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology, 2018, 74, 309-321.	0.9	51
46	Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma. European Urology Oncology, 2019, 2, 505-514.	2.6	50
47	Prognostication in Kidney Cancer: Recent Advances and Future Directions. Journal of Clinical Oncology, 2018, 36, 3567-3573.	0.8	49
48	Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis. European Urology Open Science, 2022, 37, 14-26.	0.2	48
49	The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients. Targeted Oncology, 2013, 8, 203-209.	1.7	47
50	The prospect of precision therapy for renal cell carcinoma. Cancer Treatment Reviews, 2016, 49, 37-44.	3.4	46
51	A retrospective, Canadian multiâ€center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castrationâ€resistant prostate cancer. Prostate, 2014, 74, 1544-1550.	1.2	45
52	Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. European Urology, 2020, 78, 615-623.	0.9	44
53	Programmed Death 1 Pathway inhibition in Metastatic Renal Cell Cancer and Prostate Cancer. Current Oncology Reports, 2013, 15, 98-104.	1.8	41
54	Characterizing the Impact of Lymph Node Metastases on the Survival Outcome for Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapies. European Urology, 2015, 68, 506-515.	0.9	41

#	Article	IF	Citations
55	Outcomes with Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Who Have Poor Performance Status. European Urology, 2015, 67, 441-447.	0.9	40
56	Integrative clinical and molecular characterization of translocation renal cell carcinoma. Cell Reports, 2022, 38, 110190.	2.9	40
57	Anti-Angiogenic Targets in the Treatment of Advanced Renal Cell Carcinoma. Current Cancer Drug Targets, 2008, 8, 676-682.	0.8	38
58	Characterizing the outcomes of metastatic papillary renal cell carcinoma. Cancer Medicine, 2017, 6, 902-909.	1.3	37
59	Adjuvant therapy in renal cell carcinoma. Cancer Treatment Reviews, 2017, 60, 152-157.	3.4	35
60	Treatment Selection in First-line Metastatic Renal Cell Carcinomaâ€"The Contemporary Treatment Paradigm in the Age of Combination Therapy. JAMA Oncology, 2022, 8, 292.	3.4	35
61	Nonâ€"Clear Cell Renal Cancer: Features and Medical Management. Journal of the National Comprehensive Cancer Network: JNCCN, 2009, 7, 659-665.	2.3	32
62	The use of prognostic factors in metastatic renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 509-516.	0.8	32
63	Contemporary treatment of metastatic renal cell carcinoma. Oncology Reviews, 2016, 10, 295.	0.8	32
64	First-line sunitinib or pazopanib in metastatic renal cell carcinoma: The Canadian experience. Canadian Urological Association Journal, 2017, 11, 112.	0.3	32
65	Cytoreductive Nephrectomy in Metastatic Papillary Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2019, 2, 643-648.	2.6	31
66	Prolonged Complete Responses and Near-Complete Responses to Sunitinib in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2007, 5, 446-451.	0.9	30
67	Canadian guideline on genetic screening for hereditary renal cell cancers. Canadian Urological Association Journal, 2013, 7, 319.	0.3	30
68	The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians. Canadian Urological Association Journal, 2017, 11, 379-87.	0.3	29
69	Synchronous Versus Metachronous Metastatic Disease: Impact of Time to Metastasis on Patient Outcomeâ€"Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology Oncology, 2020, 3, 530-539.	2.6	29
70	Prognostic and predictive biomarkers in renal cell carcinoma. Targeted Oncology, 2010, 5, 85-94.	1.7	27
71	Clinical and Molecular Prognostic Factors in Renal Cell Carcinoma: What We Know So Far. Hematology/Oncology Clinics of North America, 2011, 25, 871-891.	0.9	27
72	Current management and future perspectives of metastatic renal cell carcinoma. International Journal of Urology, 2014, 21, 847-855.	0.5	27

#	Article	IF	Citations
73	Risk factors and model for predicting toxicityâ€related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factorâ€“targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer, 2016, 122, 411-419.	2.0	27
74	Efficacy of Targeted Therapy for Metastatic Renal Cell Carcinoma in the Elderly Patient Population. Clinical Genitourinary Cancer, 2014, 12, 354-358.	0.9	26
75	Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors. European Urology Oncology, 2021, 4, 102-111.	2.6	26
76	A Population-Based Overview of Sequences of Targeted Therapy in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, e127-e131.	0.9	25
77	Personalized Management of Advanced Kidney Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 330-341.	1.8	25
78	An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma. European Urology Focus, 2020, 6, 34-36.	1.6	25
79	New approaches to first-line treatment of advanced renal cell carcinoma. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110347.	1.4	25
80	Health-related quality of life and disease symptoms in postmenopausal women with HR⁺, HER2^{â^'}advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. Current Medical Research and Opinion, 2013, 29, 1463-1473.	0.9	24
81	Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials. European Journal of Cancer, 2021, 151, 115-125.	1.3	22
82	Cabozantinib realâ€world effectiveness in the firstâ€through fourthâ€line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Cancer Medicine, 2021, 10, 1212-1221.	1.3	22
83	The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factorâ€targeted therapy. Cancer, 2012, 118, 365-370.	2.0	21
84	Assessment of Immune Checkpoint Inhibitors and Genomic Alterations by Body Mass Index in Advanced Renal Cell Carcinoma. JAMA Oncology, 2021, 7, 773.	3.4	21
85	Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. Therapeutic Advances in Urology, 2016, 8, 338-347.	0.9	20
86	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	2.6	20
87	New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials. Cancer Treatment Reviews, 2015, 41, 614-622.	3.4	19
88	Management of advanced kidney cancer: Canadian Kidney Cancer Forum consensus update. Canadian Urological Association Journal, 2015, 9, 164.	0.3	18
89	Adult patient perspectives on clinical trial result reporting: A survey of cancer patients. Clinical Trials, 2016, 13, 574-581.	0.7	17
90	The promise of futility trials in neurological diseases. Nature Reviews Neurology, 2015, 11, 300-305.	4.9	16

#	Article	IF	Citations
91	Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592211086.	1.4	15
92	Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis. Critical Reviews in Oncology/Hematology, 2015, 93, 50-59.	2.0	14
93	Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy. European Journal of Cancer, 2022, 171, 124-132.	1.3	14
94	Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. European Urology, 2017, 71, 970-978.	0.9	12
95	Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group. Oncologist, 2020, 25, 422-430.	1.9	12
96	Real-world evidence in metastatic renal cell carcinoma. Tumori, 2018, 104, 76-82.	0.6	11
97	Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. Journal of Urology, 2021, 205, 78-85.	0.2	11
98	Management of advanced kidney cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2021. Canadian Urological Association Journal, 2020, 15, 84-97.	0.3	11
99	Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy. JAMA Network Open, 2021, 4, e2116536.	2.8	11
100	Characteristics of Long-Term and Short-Term Survivors of Metastatic Renal Cell Carcinoma Treated With Targeted Therapies: Results From the International mRCC Database Consortium. Clinical Genitourinary Cancer, 2015, 13, 150-155.	0.9	10
101	Fourth-Line Therapy in Metastatic Renal Cell Carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC)1. Kidney Cancer, 2018, 2, 31-36.	0.2	10
102	Management of Advanced Kidney Cancer: Kidney Cancer Research Network of Canada (KCRNC) consensus update 2019. Canadian Urological Association Journal, 2019, 13, 343-54.	0.3	10
103	The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma. Current Opinion in Urology, 2019, 29, 507-512.	0.9	10
104	Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) â€“ an International mRCC Database Consortium (IMDC) analysis. Journal of Geriatric Oncology, 2021, 12, 820-826.	0.5	10
105	The Evolving Landscape of Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 299-302.	1.8	10
106	Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Database. Current Oncology, 2021, 28, 4213-4222.	0.9	10
107	The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer. Current Oncology, 2021, 28, 107-114.	0.9	10
108	Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma. JAMA Network Open, 2022, 5, e2216379.	2.8	10

#	Article	IF	Citations
109	New insights into the obesity paradox in renal cell carcinoma. Nature Reviews Nephrology, 2020, 16, 253-254.	4.1	9
110	Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis. European Urology Open Science, 2022, 39, 62-71.	0.2	9
111	Metastatic renal cell carcinoma: Contending with a sea change in therapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 507-508.	0.8	8
112	Considerations for the Design of Future Clinical Trials in Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 1-12.	0.9	7
113	Management of metastatic kidney cancer in the era of personalized medicine. Critical Reviews in Clinical Laboratory Sciences, 2014, 51, 85-97.	2.7	6
114	Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. Cancer Journal (Sudbury, Mass) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.6	6
115	Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated with Targeted Therapies. Journal of Kidney Cancer and VHL, 2016, 3, 12-22.	0.2	6
116	Combining Radiotherapy with Immunocheckpoint Inhibitors or CAR-T in Renal Cell Carcinoma. Current Drug Targets, 2020, 21, 416-423.	1.0	6
117	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. Clinical Genitourinary Cancer, 2021, 19, 354-361.	0.9	5
118	Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. European Urology Focus, 2022, 8, 1703-1710.	1.6	5
119	Risk Prediction Using Bayesian Networks: An Immunotherapy Case Study in Patients With Metastatic Renal Cell Carcinoma. JCO Clinical Cancer Informatics, 2021, 5, 326-337.	1.0	4
120	Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical Genitourinary Cancer, 2022, 20, 210-218.	0.9	4
121	On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?. Expert Review of Anticancer Therapy, 2017, 17, 97-99.	1.1	3
122	Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2020, 18, e350-e359.	0.9	3
123	Real-Word Experience of Cabozantinib in Metastatic Renal Cell Carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis). Kidney Cancer, 2021, 5, 21-29.	0.2	3
124	Post-chemotherapy retroperitoneal lymph node dissection for non-seminomatous germ cell tumors: A single-surgeon, Canadian experience. Canadian Urological Association Journal, 2020, 14, E407-E411.	0.3	2
125	Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors. Cancer Medicine, 2021, 10, 2618-2626.	1.3	2
126	Independent Predictors of Clinical Outcomes and Prediction Models for Renal Tumor Pathology. , 2015, , 355-371.		2

#	Article	IF	Citations
127	Combination therapy in metastatic renal cell carcinoma. Lancet Oncology, The, 2011, 12, 613-614.	5.1	1
128	Stage migration of testicular germ cell tumours in Alberta, Canada, during the COVID-19 pandemic: a retrospective cohort study. CMAJ Open, 2022, 10, E633-E642.	1.1	1
129	Prognostic Factors in Advanced Renal Cell Carcinoma. , 2013, , 249-255.		0
130	Predictive and Prognostic Markers in Metastatic Renal Cell Carcinoma. , 2017, , 237-251.		0
131	In Reply. Oncologist, 2017, 22, 1561-1561.	1.9	0
132	Reply By Authors. Journal of Urology, 2021, 205, 84-85.	0.2	0
133	Interactive Data Visualization Tool for Patient-Centered Decision Making in Kidney Cancer. JCO Clinical Cancer Informatics, 2021, 5, 912-920.	1.0	0
134	Clinical Prognostic Factors in Metastatic Renal Cell Carcinoma. , 2015, , 555-567.		0
135	Mutational signatures among young-onset testicular cancers. BMC Medical Genomics, 2021, 14, 280.	0.7	0